Unlocking the Power of Light on the Skin: A Comprehensive Review on Photobiomodulation

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(8), P. 4483 - 4483

Published: April 19, 2024

Photobiomodulation (PBM) is a procedure that uses light to modulate cellular functions and biological processes. Over the past decades, PBM has gained considerable attention for its potential in various medical applications due non-invasive nature minimal side effects. We conducted narrative review including articles about photobiomodulation, LED therapy or low-level laser their on dermatology published over last 6 years, encompassing research studies, clinical trials, technological developments. This highlights mechanisms of action underlying PBM, interaction with chromophores activation intracellular signaling pathways. The evidence from trials experimental studies evaluate efficacy practice summarized special emphasis dermatology. Furthermore, advancements technology, such as novel sources treatment protocols, are discussed context optimizing therapeutic outcomes improving patient care. underscores promising role approach broad applicability. Despite need further develop standard holds great addressing wide range conditions enhancing modern healthcare practice.

Language: Английский

---

Interleukin-17: A Pleiotropic Cytokine Implicated in Inflammatory, Infectious, and Malignant Disorders

Cytokine & Growth Factor Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.

PubMed, Journal Year: 2024, Volume and Issue: 23, P. 300 - 334

Published: Jan. 1, 2024

Cutaneous Squamous Cell Carcinoma (cSCC) is a common and potentially fatal type of skin cancer that poses significant threat to public health has high prevalence rate. Exposure ultraviolet radiation on the surface increases risk cSCC, especially in those with genetic syndromes like xerodermapigmentosum epidermolysis bullosa. Therefore, understanding molecular pathogenesis cSCC critical for developing personalized treatment approaches are effective cSCC. This article provides comprehensive overview current knowledge pathogenesis, emphasizing dysregulated signaling pathways significance profiling. Several limitations challenges associated conventional therapies, however, identified, stressing need novel therapeutic strategies. The further discusses targets approaches, i.e., epidermal growth factor receptor inhibitors, hedgehog pathway PI3K/AKT/mTOR as well emerging agents. manuscript explores resistance mechanisms molecularly targeted therapies proposes methods overcome them, including combination strategies, rational design, optimization. clinical implications patient outcomes molecular-targeted treatments assessed, response rates survival outcomes. management adverse events toxicities crucial requires careful monitoring control. paper future directions advancement research this area, difficulties constraints therapies.

Language: Английский

---

A Patient With Concurrent Hidradenitis Suppurativa and Porokeratosis Palmaris et Plantaris Disseminata: Case Report and Review of Autoinflammatory Keratinization Diseases

Journal of Cutaneous Pathology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

ABSTRACT The term autoinflammatory keratinization diseases (AIKDs) was recently proposed as a unifying concept for characterized by inflammation in the epidermis and upper dermis which leads to hyperkeratosis, caused genetic perturbations of innate immune system. We present case patient with hidradenitis suppurativa porokeratosis, two AIKDs, followed review these conditions well other AIKDs. This distinguished hypertrophic porokeratoses involving cystic hair follicles, showing histopathologic features both within single biopsy specimens. patient's course additionally complicated SCC arising porokeratosis. Our demonstrates rare overlap occurring not only same but also lesions.

Language: Английский

---

Unravelling the role of the skin microbiome in immunodermatological diseases: implications for therapeutic interventions

International Journal of Research in Dermatology, Journal Year: 2025, Volume and Issue: 11(2), P. 190 - 198

Published: Feb. 24, 2025

The skin microbiome, comprising diverse microbial communities, is pivotal in maintaining cutaneous homeostasis and modulating immune responses immunodermatological diseases. This review provides an overview of recent research investigating the interplay between microbiome autoimmune, allergic, inflammatory conditions, such as psoriasis, eczema, acne vulgaris. Current evidence suggests that alterations composition, termed dysbiosis, may contribute to disease pathogenesis exacerbate inflammation disorders. Furthermore, microbial-derived metabolites immune-modulating factors produced by commensal bacteria can influence local barrier function. Future directions include evaluating how interacts with host system, identifying biomarkers for diagnosis prognosis, exploring microbiome-targeted therapeutic interventions, probiotics, transplantation, metabolite supplementation. By leveraging insights from research, personalized approaches managing diseases offer novel avenues restoring improving patient outcomes.

Language: Английский

---

Advancements in Early Diagnosis and Personalized Treatment Strategies for Skin Diseases: A Meta-Analysis of Interdisciplinary Approaches Combining Dermatology, Genetics, and Immunology

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 15, 2025

Several Skin illnesses, including dermatological disorders psoriasis, eczema, and skin cancers, remain serious issues to the health of humankind. Advances in diagnostic technology, treatment practices, cross-disciplinary studies recent past have potential revolutionize management these diseases. This meta-analysis is aimed explore novel developments early diagnosis personalized regimens with a focus on integration dermatology genetics, immunology, other clinical sciences. We will address emerging techniques, such as AI-based imaging, biomarkers, how they impact identification care disease its earliest form. Besides, we examine latest medicine treatments, biologics targeted therapies, which been promising improve outcomes patients. There need for interdisciplinary cooperation between genetics order maximize protocols advance knowledge biology. review also assess preventative strategies, genetic testing, lifestyle modifications, treatment, mitigate progression chronic disorders. By collating data across disciplines, this research yield an integrative summary practice future ultimately enhance quality life individuals further boundaries science. review, way that global initiatives can increase access new therapies ensure technological advancements dermatologic become available diverse groups people be discussed. Bridging gaps healthcare infrastructure, especially low-resource environments, vital move towards alleviating burden disease.

Language: Английский

---

Basal cell carcinoma in situ of the skin revisited: case reports of the superficial type and fibroepithelioma type of this in situ cutaneous neoplasm

Dermatology Online Journal, Journal Year: 2024, Volume and Issue: 30(1)

Published: March 15, 2024

Cutaneous basal cell carcinoma in situ is a recently proposed subtype of this skin cancer. It characterized by either restriction the tumor cells within epidermis or presence contiguous with overlying that extend into underlying dermis, both. Importantly, cancer invasion-demonstrated non-contiguous aggregates basaloid dermis-is not feature skin. A 63-year-old woman cutaneous situ-superficial type presented as an erythematous scaly plaque on her abdomen and 61-year-old man situ-fibroepithelioma flesh-colored smooth exophytic nodule his back are reported. The characteristics these individuals summarized. In conclusion, similar to other malignant neoplasms-such squamous carcinoma, melanoma, Merkel carcinoma-basal can also present

Language: Английский

---

Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa

Current Drug Targets, Journal Year: 2024, Volume and Issue: 25(6), P. 404 - 415

Published: April 1, 2024

Epidermolysis bullosa (EB) is an inherited skin disease representing a spectrum of rare genetic disorders. These conditions share the common trait that causes fragile skin, resulting in development blisters and erosions. The inheritance follows autosomal pattern, array clinical presentations leads to significant physical suffering, considerable morbidity, mortality. Despite EB having no cure, effectively managing remains exceptional challenge due its rarity complexity, occasionally casting profound impact on lives affected individuals. Considering management requires multidisciplinary approach, this sometimes worsens condition patients with inappropriate handling. Thus, more appropriate precise treatment essentially needed. Advanced technology medicine health comes into bioinformatics era. Including for diseases, omics-based approaches aim evaluate handle better treatment. In work, we review several regarding implementation technology, including genetics, pathogenic mutation, microbiomics, metagenomics analysis EB. addition, highlight recent updates potential precision

Language: Английский

---

Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point

Pharmacopsychiatry, Journal Year: 2024, Volume and Issue: 57(06), P. 263 - 274

Published: Aug. 19, 2024

The future of depression pharmacotherapy lies in a precision medicine approach that recognizes is disease where different causalities drive symptoms. That calls for departure from current diagnostic categories, which are broad enough to allow adherence the "one-size-fits-all" paradigm, complementary routine use "broad-spectrum" mono-amine antidepressants. Similar oncology, narrowing overinclusive window by implementing laboratory tests, guide specifically targeted treatments, will be major step forward overcoming present drug discovery crisis.A substantial subgroup patients presents with signs and symptoms hypothalamic-pituitary-adrenocortical (HPA) overactivity. Therefore, this stress hormone system was considered offer worthwhile targets. Some promising results emerged, but sum, achieved targeting corticosteroid receptors were mixed.More specific non-peptidergic drugs block stress-responsive neuropeptides, corticotropin-releasing (CRH), arginine vasopressin (AVP) brain antagonizing their cognate CRHR1-and V1b-receptors. If patient's depressive symptomatology driven overactive V1b-signaling then V1b-receptor antagonist should first-line treatment. To identify patient having overactivity, neuroendocrine test, so-called dex/CRH-test, developed, indicates central AVP release too complicated routinely used. test transformed into gene-based "near-patient" allows immediate identification if depressed signaling. We believe next innovation depression.

Language: Английский

---

Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?

Clinical & Experimental Metastasis, Journal Year: 2023, Volume and Issue: 41(4), P. 439 - 445

Published: Dec. 8, 2023

Language: Английский

---